Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study ...

ulcerative colitis, inflammatory bowel disease, IBD, UC Researchers performed a systematic review of clinical trials to assess the need for a consensus on the definition of mild to moderate, active ...

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...

Share on Pinterest New research is testing the medication tulisokibart in treating ulcerative colitis. Maria Korneeva/Getty Images Ulcerative colitis is a type of inflammatory bowel disease (IBD) and ...

Zeposia is the first oral sphingosine-1-phosphate (S1P) receptor modulator to demonstrate benefit in moderate to severe ulcerative colitis in a Phase 3 study PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol ...

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy ...

Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, led to clinically meaningful improvements in patients with moderately to severely active ulcerative colitis ...

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...

Please provide your email address to receive an email when new articles are posted on . Zeposia (Ozanimod, Bristol Myers Squibb), the first sphingosine 1-phosphate (S1P) receptor modulator approved ...